Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Pre-Transplantation Predictors of Survival in Patients Undergoing Allogeneic Stem Cell Transplant for Myelofibrosis

Jeanne Palmer, MD, Tania Jain, MD, Katie L. Kunze, PhD, Daniel K. Partain, MD, Nandita Khera, MD, Lisa Sproat, MD MSW, Pierre Noel, MD, James L. Slack, MD, Vivek Roy, MD, Jose F. Leis, MD PhD, William J. Hogan, MBBCh, Ayalew Tefferi, MD, Veena D. S. Fauble, MD, Mrinal M. Patnaik, MDMBBS, Heidi Elizabeth Kosiorek, MS, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 4598.

https://doi.org/10.1182/blood.V130.Suppl_1.4598.4598

Published: 2017

Journal Articles

Transfusion Dependence at Day +100 Predicts Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation for Myelofibrosis

Tania Jain, MD, Katie L. Kunze, PhD, Daniel K. Partain, MD, Heidi Kosiorek, MS, Vivek Roy, MD, Nandita Khera, MD, James L. Slack, MD, Mrinal M. Patnaik, MDMBBS, William J. Hogan, MBBCh, Pierre Noel, MD, Veena D. S. Fauble, MD, Jose F. Leis, MD PhD, Lisa Sproat, MD MSW, Ruben A Mesa, MD, Jeanne Palmer, MD

Blood (2017) 130 (Supplement 1): 4561.

https://doi.org/10.1182/blood.V130.Suppl_1.4561.4561

Published: 2017

Journal Articles

Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis

Tania Jain, M.B.,B.S, M'hamed Temkit, Daniel K. Partain, MD, Mrinal M Patnaik, MBBS, James L. Slack, MD, Nandita Khera, MD, William J. Hogan, MBChB, Vivek Roy, MD, Pierre Noel, MD, Jose F Leis, MD PhD, Lisa Sproat, MD MSW, Veena DS Fauble, MD, Ruben A. Mesa, MD, Jeanne Palmer, MD

Blood (2016) 128 (22): 4653.

https://doi.org/10.1182/blood.V128.22.4653.4653

Published: 2016

Journal Articles

Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes

Moussab Damlaj, MD, Hassan B Alkhateeb, MD, Mehrdad Hefazi, MD, Daniel K. Partain, MD, Aref Al-Kali, MD, Shahrukh K. Hashmi, MD, Naseema Gangat, MBBS, Mark R Litzow, MD, William J Hogan, MBChB, Mrinal M Patnaik, MBBS

Blood (2015) 126 (23): 3210.

https://doi.org/10.1182/blood.V126.23.3210.3210

Published: 2015

Journal Articles

The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly

Daniel K. Partain, MD, Moussab Damlaj, MD, Aref Al-Kali, MD, Naseema Gangat, MBBS, Mark R Litzow, MD, William J Hogan, MBChB, Shahrukh K. Hashmi, MD, Wilson I. Gonsalves, MD, James M. Foran, MD, Vivek Roy, MD FACP, Ruben A. Mesa, Jeanne Palmer, MD, James L. Slack, MD, Mrinal M Patnaik, MBBS

Blood (2015) 126 (23): 4370.

https://doi.org/10.1182/blood.V126.23.4370.4370

Published: 2015

Journal Articles

Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing

Moussab Damlaj, MD, Hassan B Alkhateeb, MD, Daniel K. Partain, MD, Jehad Almasri, MD, Mehrdad Hefazi, MD, Shahrukh K. Hashmi, MD, Dennis A. Gastineau, MD, Aref Al-Kali, MD, Robert C Wolf, PharmD, Naseema Gangat, MBBS, Mark R Litzow, MD, William J Hogan, MBChB, Mrinal M Patnaik, MBBS

Blood (2015) 126 (23): 736.

https://doi.org/10.1182/blood.V126.23.736.736

Published: 2015

NARROW

Pre-Transplantation Predictors of Survival in Patients Undergoing Allogeneic Stem Cell Transplant for Myelofibrosis

Transfusion Dependence at Day +100 Predicts Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation for Myelofibrosis

Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis

Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes

The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly

Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing

Email alerts

ASH Publications

American Society of Hematology

Pre-Transplantation Predictors of Survival in Patients Undergoing Allogeneic Stem Cell Transplant for Myelofibrosis

Transfusion Dependence at Day +100 Predicts Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation for Myelofibrosis

Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis

Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes

The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly

Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only